huPBMC-(M-NSG)

PBMC人源化（hPBMC）小鼠是用来进行传染病、GvHD及肿瘤免疫的有效模型。人源PBMC中的T细胞受到小鼠异种抗原刺激而增殖，其他类型细胞则维持较低含量或过早消亡。PBMC人源化小鼠体内的人源细胞以T细胞为主，适合需要T细胞免疫反应的各类研究。但T细胞也会对受体小鼠进行过度免疫攻击，进而引发移植物抗宿主病（GvHD），并可在数周之后引起小鼠死亡。所以PBMC人源化小鼠可供实验的窗口期较短，只适合于短期性研究。

表型分析

Fig. Flow analysis of peripheral blood lymphocyte subpopulations in the Hu-PBMC model. Human PBMCS (5E6) was injected intravenously into M-NSG mice (female, 6 weeks old, n=6). Blood was taken at different time points after implantation of humanPBMCS for flow cytometric analysis.

药效评价

基于肠癌Hu-PBMC模型的抗肿瘤药效验证

Fig. In vivo pharmacodynamic studies using the Hu-PBMC model of intestinal cancer (HT29).

基于人小细胞肺癌Hu-PBMC模型的双抗药物抗肿瘤药效验证

Fig. In vivo efficacy studies using the human small cell lung cancer (SHP-77) Hu-PBMC model.

基于人结直肠癌Hu-PBMC模型的CAR-NK疗法抗肿瘤药效验证

Fig. In vivo CAR-NK efficacy study using the human colorectal cancer (LoVo) Hu-PBMC model.